Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Decision Resources Group
Decision Resources Group
Activities:
Media
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Media
Chilean pharmaceutical market expected to increase at CAGR of 11.3% over next five years
Pharma landscape is small but highly competitive, finds new report from Decision Resources Group
You need to be a subscriber to read this article.
Click here
to find out more.
Drug Delivery
Drug delivery innovations set to disrupt sector
Drug formulators will have a broader range of drug delivery options in future, aiding both compliance and outcomes. Susan Birks reports
Media
Colombian pharmaceutical market expected to reach US$5.37bn by 2016
Provides an entry point into South America for multinational pharmaceutical companies
Vietnam bans companies making \'substandard\' drugs
Companies banned include 45 Indian pharmaceutical companies along with others from Korea, France and Pakistan
Media
Global biosimilars pipeline has expanded by more than 40% in 12 months, finds report
Strong growth in Brazil driven by public-private partnerships
Pharmaceutical
Biosimilars
9 April 2014, One-day seminar, London, UK
Media
Piramal Healthcare buys Decision Resources Group
Indian firm pays US$635m for healthcare information business
Subscribe now